Dr. Peter Dudek

Dr. Peter Dudek

Principal

Biography

Peter joined Wellington Partners in February 2016 as a Principal. Prior to joining Wellington, Peter was an Investment Associate at Entrepreneurs Fund, a London-based pan-European venture fund with more than $200m of assets under management. Peter served as a Board Observer on Vasopharm and Optinose, and supported multiple transactions across the life sciences portfolio including investments in Vasopharm, Optinose, Cytoo, Sequana Medical and Prosonix, as well as Prosonix’s sale to Circassia.

Before EF, Peter consulted for a number of European venture-backed biotechnology startups and was an interned Analyst at Novartis Venture Funds. In his prior life as a scientist, Peter worked in the field of ncRNAs and chromatin remodelling as a Research Fellow at the University of Oxford (Queen’s), obtained his PhD from the University of Geneva in oncology, and a BSc (Hons) in immunology from the University of British Columbia. He also conducted research on the Hepatitis C virus at the BC Centre for Disease Control.